Current Report Filing (8-k)
February 17 2017 - 5:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): February 11, 2017
Kiwa
Bio-Tech Products Group Corporation
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
000-33167
|
|
77-0632186
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
310
N. Indian Hill Blvd., #702
|
|
|
Claremont,
California
|
|
91711
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (626) 715-5855
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Item
1.01 Entry into a Material Definitive Agreement.
On
February 11, 2017, Kiwa Bio-Tech Products Group Corporation (OTC: KWBT) (the “Company”) executed an Equity Transfer
Agreement with Dian Shi Cheng Jing (Beijing) Technology Co. (“Transferee”) whereby the Company transferred all of
its right, title and interest in Kiwa Bio-Tech Products (Shandong) Co., Ltd. (“Shandong”) to the Transferee for the
RMB equivalent of US$1.00. In connection with the transaction, the Transferee received all assets of Shandong which are estimated
to be approximately RMB 14,057,713 at the effective date and assumed all liabilities of Shandong which are estimated to be approximately
RMB59,446,513 at the effective date. In connection with this transaction, Transferee agreed to indemnify the Company for any liability
or claims of any third party(ies) against Shandong or the Company for five (5) years. The transaction is subject to obtaining
Chinese government approval for the transaction, which the parties agrees to use their best efforts to obtain prior to December
31, 2017.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
None
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
February 17, 2017
|
Kiwa
Bio-Tech Products Group Corporation
|
|
|
|
By:
|
/s/
Yvonne Wang
|
|
Name:
|
Yvonne
Wang
|
|
Title:
|
Chief
Executive Officer
|
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Apr 2024 to May 2024
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From May 2023 to May 2024